Crinetics Pharmaceuticals, Inc. — Cyborg Score 7/10
Strong
Biopharmaceutical - Specialty Endocrinology
Strategic Profile
Crinetics is focused on discovering, developing, and commercializing novel therapies, with a core expertise in targeting G-protein coupled receptors (GPCRs) with small molecules that have specifically tailored pharmacology and properties. The company raised approximately $350 million in gross proceeds from a January 2026 public offering to fund PALSONIFY launch and an extensive pipeline of 10+ programs in clinical development.
Cyborg Score Rationale
PALSONIFY is the first FDA-approved oral treatment for acromegaly, representing significant commercial validation. In December 2025, atumelnant entered Phase 3 clinical trials for congenital adrenal hyperplasia, demonstrating strong pipeline momentum. Recent $350M financing positions the company well to execute launches and development.
Top Insights
PALSONIFY is approved for acromegaly with inadequate surgical response; paltusotine is also in clinical development for carcinoid syndrome
Phase 3 atumelnant trial for congenital adrenal hyperplasia initiated December 2025 following positive Phase 2 data
Pipeline includes programs for graves' disease, thyroid eye disease, autosomal dominant polycystic kidney disease, obesity treatments, and multiple solid tumors
Strong liquidity position with current ratio of 15.1 and low debt-to-equity of 0.05
Named Competitors
Somavert — Pegvisomant for acromegaly
Sandostatin — Octreotide for acromegaly and neuroendocrine tumors
Somatuline — Lanreotide for acromegaly and neuroendocrine tumors
Recent Developments
(February 2026) Fourth quarter and full year 2025 financial results scheduled for reporting February 26, 2026
(January 2026) Completed $350 million public offering at $45.95 per share
(December 2025) First patient dosed in Phase 3 atumelnant trial for congenital adrenal hyperplasia
(January 2026) Announced strong PALSONIFY launch execution and positive concurrent biomarker results in Phase 2 atumelnant study
Open the full interactive Crinetics Pharmaceuticals, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.